Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers

Cancer Research
Filip MundtCynthia X Ma

Abstract

Activation of PI3K signaling is frequently observed in triple-negative breast cancer (TNBC), yet PI3K inhibitors have shown limited clinical activity. To investigate intrinsic and adaptive mechanisms of resistance, we analyzed a panel of patient-derived xenograft models of TNBC with varying responsiveness to buparlisib, a pan-PI3K inhibitor. In a subset of patient-derived xenografts, resistance was associated with incomplete inhibition of PI3K signaling and upregulated MAPK/MEK signaling in response to buparlisib. Outlier phosphoproteome and kinome analyses identified novel candidates functionally important to buparlisib resistance, including NEK9 and MAP2K4. Knockdown of NEK9 or MAP2K4 reduced both baseline and feedback MAPK/MEK signaling and showed synthetic lethality with buparlisib in vitro A complex in/del frameshift in PIK3CA decreased sensitivity to buparlisib via NEK9/MAP2K4-dependent mechanisms. In summary, our study supports a role for NEK9 and MAP2K4 in mediating buparlisib resistance and demonstrates the value of unbiased omic analyses in uncovering resistance mechanisms to targeted therapy.Significance: Integrative phosphoproteogenomic analysis is used to determine intrinsic resistance mechanisms of triple-negative...Continue Reading

References

Feb 14, 2006·Structure·Maria M García-AlaiGonzalo de Prat-Gay
May 30, 2006·Molecular Cancer Therapeutics·Seiji Fukuda, Louis M Pelus
Sep 16, 2006·The Journal of Biological Chemistry·Martin P PlayfordMichael D Schaller
Feb 24, 2007·The EMBO Journal·Addolorata Maria Luce ColucciaCarlo Gambacorti-Passerini
Jun 3, 2009·Molecular and Cellular Biology·Hugo A Acosta-JaquezDiane C Fingar
Jan 8, 2011·The Oncologist·James S Welsh
Jul 23, 2011·Genes & Cancer·Esther Castellano, Julian Downward
Mar 27, 2012·The Journal of Clinical Investigation·Cynthia X MaHelen Piwnica-Worms
Nov 8, 2012·Journal of Cell Science·Andrew M FryRichard Bayliss
Feb 13, 2013·Nature Reviews. Clinical Oncology·Jordi RodonJosep Tabernero
Nov 15, 2013·Bioinformatics·Jianfei HuJiang Qian
Jul 22, 2014·Nature·Bing ZhangUNKNOWN NCI CPTAC
Sep 4, 2014·Cancer Discovery·Manuel HidalgoAlberto Villanueva
Nov 6, 2015·Analytical Chemistry·Nicholas M Riley, Joshua J Coon
Nov 14, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Cynthia X MaMatthew J Ellis
Dec 4, 2015·Molecular & Cellular Proteomics : MCP·Kelly V RugglesDavid Fenyő
Jun 3, 2016·Nature·Philipp MertinsUNKNOWN NCI CPTAC
Mar 30, 2017·Nature Communications·Kuan-Lin HuangLi Ding

❮ Previous
Next ❯

Citations

Mar 10, 2020·PLoS Computational Biology·Arshag D MooradianJason M Held
Jun 15, 2019·Molecular & Cellular Proteomics : MCP·Kuan-Lin HuangLi Ding
Jan 29, 2020·Nature Communications·Shankha SatpathyMatthew J Ellis
Jun 25, 2020·Cancer Metastasis Reviews·Belinda J Petri, Carolyn M Klinge
Feb 21, 2019·Molecular Cancer·Jing YangXiawei Wei
Oct 28, 2019·Breast Cancer Research and Treatment·Nathan M MerrillMatthew B Soellner
Mar 1, 2019·Molecular & Cellular Proteomics : MCP·Karsten KrugD R Mani
Aug 1, 2019·Molecular & Cellular Proteomics : MCP·Kuan-Lin HuangLi Ding
Feb 16, 2020·Cell·Yongchao DouUNKNOWN Clinical Proteomic Tumor Analysis Consortium
Feb 26, 2021·Genomics, Proteomics & Bioinformatics·Xi ChengJing Li
Apr 19, 2021·Critical Reviews in Oncology/hematology·Silvia Rita VitalePaolo Vigneri
Jun 25, 2021·Journal of Proteome Research·Lili BlumenbergDavid Fenyö
Dec 26, 2018·Journal of Proteome Research·Praveen KumarPratik D Jagtap
Aug 31, 2021·The Journal of Biological Chemistry·Ali E YesilkanalMarsha Rich Rosner
Sep 28, 2021·Molecular Systems Biology·Hasmik KeshishianSteven A Carr
Aug 13, 2021·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Adam J LinleyJoseph R Slupsky

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.